Y
Yozo Nakazawa
Researcher at Shinshu University
Publications - 233
Citations - 3104
Yozo Nakazawa is an academic researcher from Shinshu University. The author has contributed to research in topics: Hematopoietic stem cell transplantation & Chimeric antigen receptor. The author has an hindex of 25, co-authored 210 publications receiving 2526 citations. Previous affiliations of Yozo Nakazawa include Baylor College of Medicine & Tokyo University of Agriculture.
Papers
More filters
Journal ArticleDOI
piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.
Pallavi R. Manuri,Matthew H. Wilson,Sourindra Maiti,Tiejuan Mi,Harjeet Singh,Simon Olivares,Margaret J. Dawson,Helen Huls,Dean A. Lee,Pulivarthi H. Rao,Joseph M. Kaminski,Yozo Nakazawa,Stephen Gottschalk,Partow Kebriaei,Elizabeth J. Shpall,Richard E. Champlin,Laurence J.N. Cooper +16 more
TL;DR: It is demonstrated that T cells electroporated to introduce the PB transposon and transposase stably express CD19-specific CAR and when cultured on CD19(+) artificial antigen-presenting cells, numerically expand in a CAR-dependent manner, display a phenotype associated with both memory and effector T cell populations, and exhibitCD19-dependent killing of tumor targets.
Journal ArticleDOI
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.
Kazuyuki Matsuda,Akira Shimada,Nao Yoshida,Atsushi Ogawa,Akihiro Watanabe,Shuhei Yajima,Susumu Iizuka,Kazutoshi Koike,Fumio Yanai,Keiichiro Kawasaki,Masakatsu Yanagimachi,Akira Kikuchi,Yoshitoshi Ohtsuka,Eiko Hidaka,Kazuyoshi Yamauchi,Miyuki Tanaka,Ryu Yanagisawa,Yozo Nakazawa,Masaaki Shiohara,Atsushi Manabe,Seiji Kojima,Kenichi Koike +21 more
TL;DR: Some children with juvenile myelomonocytic leukemia with specific RAS mutations may have spontaneously improving disease, and numbers of circulating granulocyte-macrophage progenitors were significantly reduced during the clinical course.
Journal ArticleDOI
Hemophagocytic lymphohistiocytosis: Pathogenesis, diagnosis, and management.
TL;DR: To improve outcome, it is essential to identify the disorders underlying HLH and provide disorder‐appropriate treatment and to settle the hyperactivated immunological state as soon as possible.
Journal ArticleDOI
PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor
Yozo Nakazawa,Leslie E. Huye,Leslie E. Huye,Vita S. Salsman,Vita S. Salsman,Ann M. Leen,Ann M. Leen,Nabil Ahmed,Nabil Ahmed,Lisa Rollins,Gianpietro Dotti,Gianpietro Dotti,Stephen Gottschalk,Stephen Gottschalk,Matthew H. Wilson,Matthew H. Wilson,Matthew H. Wilson,Cliona M. Rooney +17 more
TL;DR: It is demonstrated that PB can be used to redirect virus-specific, gene modified CTLs to tumor targets, which should prolong tumor-specific T cell survival in vivo producing more efficacious immunotherapy.
Journal ArticleDOI
Genome-wide mapping of PiggyBac transposon integrations in primary human T cells.
Daniel L. Galvan,Yozo Nakazawa,Aparna Kaja,Claudia Kettlun,Laurence J.N. Cooper,Cliona M. Rooney,Matthew H. Wilson,Matthew H. Wilson +7 more
TL;DR: In comparison to what has been reported for gammaretroviral and human lenitviral vectors, piggyBac had decreased integration frequency into or within 50 kb of the transcriptional start sites of known proto-oncogenes, and seems to represent a promising gene transfer system for clinical applications using human T lymphocytes.